

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Nafizal Hossain Art Unit : Unknown
Serial No. : 10/575,522 Examiner : Unknown
Filed : April 12, 2006 Conf. No. : 3659
Title : NOVEL TRICYCLIC SPIRODERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request. Copies of International Search Reports for WO 2004/005295, WO 2005/040167, WO 2005/049620, WO 2005/054249 and WO 2005/061499 are also enclosed.

Applicants provide a listing below of commonly owned co-pending U.S. patent applications that are included on the PTO-1449. Please note that the commonly owned co-pending U.S. patent applications were filed as U.S. national phase patent applications under 35 U.S.C. §371, and therefore the listing includes a reference to the PCT publication number for each of commonly owned co-pending U.S. patent applications.

The PTO-1449 lists the commonly owned co-pending U.S. patent applications by their corresponding published PCT publication numbers.

<u>U.S. Patent Application Serial No./ Published U.S. Patent Application</u>	<u>Corresponding Published PCT Patent Application</u>
US-2005-0245741-A1	WO 2004/005295 (previously cited in 4/12/06 IDS)
10/575,525	WO 2005/040167
10/579,545	WO 2005/049620
10/581,171	WO 2005/054249
10/583,468	WO 2005/061499

Applicant : Nafizal Hossain
Serial No. : 10/575,522
Filed : April 12, 2006
Page : 2 of 2

Attorney's Docket No.: 06275-503US1 / 101244-1P US

This statement is being filed before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 06275-503US1.

Respectfully submitted,

Date: March 8, 2007

Catherine M. McCarthy Reg. No. 54,301
for Janis K. Fraser, Ph.D., J.D.
Reg. No. 34,819

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

21579544.doc

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-503US1	Application No. 10/575,522
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Nafizal Hossain	
(37 CFR §1.98(b))		Filing Date April 12, 2006	Group Art Unit 1625

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
							Yes No
	AA	EP 0004951	10/31/1979	Europe			Abstract
	AB	EP 0004952	10/31/1979	Europe			Abstract
	AC	EP 0417631	03/20/1991	Europe			Abstract
	AD	EP 0722941	07/24/1996	Europe			
	AE	EP 1061076	12/20/2000	Europe			
	AF	WO 01/30780	05/03/2001	WIPO			
	AG	WO 02/102387	12/27/2002	WIPO			
	AH	WO 03/037271	05/08/2003	WIPO			
	AI	WO 2005/040167	05/06/2005	WIPO			
	AJ	WO 2005/049620	06/02/2005	WIPO			
	AK	WO 2005/054249	06/16/2005	WIPO			
	AL	WO 2005/061499	07/07/2005	WIPO			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AM	Mehrotra et al., "Spirocyclic Nonpeptide Glycoprotein IIb-IIIa Antagonists. Part 3: Synthesis and SAR of Potent and Specific 2,8-Diazaspiro[4.5]decanes", <i>Bioorganic & Medicinal Chemistry Letters</i> 12:1103-1107 (2002)
	AN	Pujol et al., "Novel tricyclic spiropiperidines. Synthesis and adrenergic activity of spiro[1,3-benzodioxolopiperidines] and spiro[1,3-benzodioxanepiperidines]", <i>Eur J Med Chem</i> 31:889-894 (1996)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	